Minerva Neurosciences | NERV - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Adma Biologics USD 477.32M 46.13M 2025-12
ALKERMES USD 1.75B 67.76M 2026-03
Alterity Therapeutics Limited AUD 36.21M 18.58M 2025-12
AstraZeneca USD 47.33B 1.33B 2026-03
BioCryst Pharmaceuticals USD -119.15M 268.74M 2025-12
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Cipla INR 329.19B 16.3B 2025-09
Clal Biotechnology ILS 121.41M 4.62M 2023-12
Compugen USD 102.73M 58.9M 2025-12
CSL USD 18.66B 2.75B 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Esperion Therapeutics USD -301.96M 149.4M 2025-12
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Grifols EUR 6.21B 133.12M 2025-12
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
J&J USD 81.19B 358M 2026-03
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novavax USD -127.75M 28.92M 2025-12
Pfizer USD 90.1B 3.63B 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sanofi EUR 72.81B 1.1B 2026-03
Takeda JPY 7.64T 513.39B 2025-12
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12